Non-Small Cell Lung Cancer New Reference: Zongertinib for her2 Mutated NSCLC Ulas D. Bayraktar, MD 2025-05-05
Bladder Cancer New Indication: Neoadjuvant Durvalumab with CISplatin/Gemcitabine for Upper GU Tract Cancer Ulas D. Bayraktar, MD 2025-05-05
Breast Cancer New Protocol: Neoadj Pembrolizumab + TP for her2+ Breast Cancer Ulas D. Bayraktar, MD 2025-05-05
Mantle cell lymphoma New Reference: Acalabrutinib with R-Bendamustine in Untreated Mantle Cell Lymphoma Ulas D. Bayraktar, MD 2025-05-04
GastroEsophageal Cancer New Protocol: Atezolizumab and Trastuzumab with CapeOx for Periop Her2+ Gastric Cancer Ulas D. Bayraktar, MD 2025-05-04
Mesothelioma New Protocol: Atezolizumab with Carbo-Pem-Bev for Pleural Mesothelioma Ulas D. Bayraktar, MD 2025-05-04
Endocrine Cancer (Non-Thyroid) New Reference: Belzutifan for vHL Associated Tumors Ulas D. Bayraktar, MD 2025-05-04
Colorectal Cancer New Reference: Neoadjuvant Dostarlimab for dMMR Tumors Ulas D. Bayraktar, MD 2025-05-04
Non-Small Cell Lung Cancer New Reference: Afatinib for NSCLC with Uncommon EGFR Mutations Ulas D. Bayraktar, MD 2025-04-22
Soft Tissue Sarcoma New Reference: Botensilimab / Balstilimab for Metastatic Sarcomas Ulas D. Bayraktar, MD 2025-04-22
